KR102359191B1 - 3-데속시 유도체 및 이의 약제학적 조성물 - Google Patents
3-데속시 유도체 및 이의 약제학적 조성물 Download PDFInfo
- Publication number
- KR102359191B1 KR102359191B1 KR1020187028967A KR20187028967A KR102359191B1 KR 102359191 B1 KR102359191 B1 KR 102359191B1 KR 1020187028967 A KR1020187028967 A KR 1020187028967A KR 20187028967 A KR20187028967 A KR 20187028967A KR 102359191 B1 KR102359191 B1 KR 102359191B1
- Authority
- KR
- South Korea
- Prior art keywords
- disease
- compound
- present
- liver
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306914P | 2016-03-11 | 2016-03-11 | |
| US62/306,914 | 2016-03-11 | ||
| PCT/US2017/021194 WO2017156024A1 (en) | 2016-03-11 | 2017-03-07 | 3-desoxy derivative and pharmaceutical compositions thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180117702A KR20180117702A (ko) | 2018-10-29 |
| KR102359191B1 true KR102359191B1 (ko) | 2022-02-04 |
Family
ID=59787771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187028967A Active KR102359191B1 (ko) | 2016-03-11 | 2017-03-07 | 3-데속시 유도체 및 이의 약제학적 조성물 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10815267B2 (https=) |
| EP (1) | EP3426348B1 (https=) |
| JP (1) | JP6892457B2 (https=) |
| KR (1) | KR102359191B1 (https=) |
| CN (1) | CN108883305B (https=) |
| AR (1) | AR107864A1 (https=) |
| AU (1) | AU2017229481B2 (https=) |
| BR (1) | BR112018068278B1 (https=) |
| CA (1) | CA3016875C (https=) |
| EA (1) | EA038632B1 (https=) |
| ES (1) | ES2874682T3 (https=) |
| IL (1) | IL261548B (https=) |
| MX (1) | MX384800B (https=) |
| PH (1) | PH12018501956A1 (https=) |
| PL (1) | PL3426348T3 (https=) |
| PT (1) | PT3426348T (https=) |
| SG (1) | SG11201807784SA (https=) |
| SI (1) | SI3426348T1 (https=) |
| TW (1) | TWI772289B (https=) |
| WO (1) | WO2017156024A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016073767A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| US11578097B2 (en) | 2014-11-26 | 2023-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof |
| JP2017535570A (ja) | 2014-11-26 | 2017-11-30 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法 |
| MX2017010376A (es) | 2015-02-11 | 2017-12-20 | Enanta Pharm Inc | Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos. |
| CA2981503C (en) | 2015-03-31 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| EP3981779A1 (en) | 2015-10-07 | 2022-04-13 | Intercept Pharmaceuticals, Inc. | Farnesoid x receptor modulators |
| WO2017147174A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
| WO2017147159A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| EP3426348B1 (en) | 2016-03-11 | 2021-05-05 | Intercept Pharmaceuticals, Inc. | 3-desoxy derivative and pharmaceutical compositions thereof |
| CA3045023A1 (en) | 2016-11-29 | 2018-06-07 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
| CA3058754A1 (en) | 2017-04-07 | 2018-10-11 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonyl carbamate bile acid derivatives |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| US20230165853A1 (en) * | 2021-01-14 | 2023-06-01 | Enyo Pharma | Method for treating chronic kidney diseases |
| WO2023288123A1 (en) | 2021-07-16 | 2023-01-19 | Interecept Pharmaceuticals, Inc. | Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid |
| US20250288600A1 (en) * | 2022-04-21 | 2025-09-18 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
| EP4611888A1 (en) * | 2022-10-31 | 2025-09-10 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1734970B1 (en) * | 2004-03-12 | 2014-12-31 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using fxr ligands |
| US20130261317A1 (en) * | 2010-09-27 | 2013-10-03 | Kythera Biopharmaceuticals, Inc. | Methods for preparing synthetic bile acids and compositions comprising the same |
| CN110041399B (zh) | 2011-12-29 | 2023-12-12 | 诺沃—诺迪斯克有限公司 | 包含非成蛋白质性的氨基酸的二肽 |
| CA2912139C (en) * | 2013-05-14 | 2021-04-20 | Roberto Pellicciari | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators |
| US10407462B2 (en) | 2014-05-29 | 2019-09-10 | Bar Pharmaceuticals S.R.L. | Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases |
| CN108137643A (zh) | 2015-08-07 | 2018-06-08 | 英特塞普特医药品公司 | 制备胆汁酸及其衍生物的方法 |
| EP3426348B1 (en) | 2016-03-11 | 2021-05-05 | Intercept Pharmaceuticals, Inc. | 3-desoxy derivative and pharmaceutical compositions thereof |
-
2017
- 2017-03-07 EP EP17763922.6A patent/EP3426348B1/en active Active
- 2017-03-07 KR KR1020187028967A patent/KR102359191B1/ko active Active
- 2017-03-07 ES ES17763922T patent/ES2874682T3/es active Active
- 2017-03-07 WO PCT/US2017/021194 patent/WO2017156024A1/en not_active Ceased
- 2017-03-07 MX MX2018010983A patent/MX384800B/es unknown
- 2017-03-07 CA CA3016875A patent/CA3016875C/en active Active
- 2017-03-07 PL PL17763922T patent/PL3426348T3/pl unknown
- 2017-03-07 US US15/451,818 patent/US10815267B2/en active Active
- 2017-03-07 BR BR112018068278-0A patent/BR112018068278B1/pt active IP Right Grant
- 2017-03-07 AU AU2017229481A patent/AU2017229481B2/en active Active
- 2017-03-07 PT PT177639226T patent/PT3426348T/pt unknown
- 2017-03-07 EA EA201892007A patent/EA038632B1/ru unknown
- 2017-03-07 SI SI201730776T patent/SI3426348T1/sl unknown
- 2017-03-07 CN CN201780018432.7A patent/CN108883305B/zh active Active
- 2017-03-07 SG SG11201807784SA patent/SG11201807784SA/en unknown
- 2017-03-07 JP JP2018547355A patent/JP6892457B2/ja active Active
- 2017-03-09 TW TW106107817A patent/TWI772289B/zh active
- 2017-03-13 AR ARP170100619A patent/AR107864A1/es unknown
-
2018
- 2018-09-03 IL IL261548A patent/IL261548B/en active IP Right Grant
- 2018-09-06 US US16/124,122 patent/US20190002493A1/en not_active Abandoned
- 2018-09-11 PH PH12018501956A patent/PH12018501956A1/en unknown
-
2020
- 2020-09-18 US US17/025,475 patent/US11319337B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102359191B1 (ko) | 3-데속시 유도체 및 이의 약제학적 조성물 | |
| US12291549B2 (en) | Farnesoid X receptor modulators | |
| EP3848038B1 (en) | 11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators | |
| HK1259145B (zh) | 3-脱氧衍生物及其药物组合物 | |
| HK1253558B (zh) | 法尼醇x受体调节剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20181008 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200306 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20211112 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20220121 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20220128 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20220128 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |